Acute gouty arthritis occurs when crystals of monosodium urate form and deposit in joints and connective tissue. These crystals then provoke the characteristic acute inflammatory response of gout (Seegmiller, 1965) , and may accumulate chronically forming gouty tophi.
Grade B, electrophoretically pure) and PIPES (Piperazine N,N'-bis (2-ethane sulfonic acid)) were purchased from Calbiochem (La Jolla, Calif.). Uricase from hog liver was obtained from Worthington Biochemical (Freehold, New Jersey).
Sodium urate was determined as uric acid (using a molecular weight of 168.11) by an enzymatic spectrophotometric method (Liddle, Seegmiller, and Laster, 1959 ) using a Gilford Model 2400 spectrophotometer. All pH determinations were made with a Corning Model 112 pH meter. Centrifugation was done in a Sorvall RC2-B centrifuge equipped with a Sorvall SS-34 head.
DETERMINATION OF URATE SOLUBILITY
To determine the urate solubility of each solution, three ml of the solution to be tested was added to a 16 ml glass test tube containing a small magnetic stirring bar. The test tubes were placed on a magnetic stirrer and maintained at the desired temperature. After 16 hours the solutions were centrifuged at 12,000g in a 6 ml glass centrifuge tube and the supernatant was removed. The centrifugation was repeated until no precipitate was visible. Two centrifugations were usually sufficient. The final supernatant was then assayed for urate. Using this procedure, urate crystals could not be detected in the final supernatant by light microscopy. Care was taken to maintain the desired temperature closely during all steps of the procedure including centrifugation.
URATE SOLUBILITY IN BUFFER SOLUTIONS
The effect of sodium on urate solubility was determined in 0-01 mol/l. potassium phosphate buffer, pH 7 40, containing appropriate amounts of sodium chloride. The desired pH was obtained by titrating solutions of monobasic and dibasic potassium phosphate.
The effect of pH on urate solubility was determined in 0-01 mol/l. sodium phosphate buffer containing 015 mol/l. sodium chloride and adjusted to the desired pH by titrating solutions of monobasic and tribasic sodium phosphate. The effect of albumin on urate solubility was determined by adding the appropriate amount of albumin to 3 ml 0 01 mol/l. sodium phosphate buffer, pH 7*40, containing 0-15 mol/l. sodium chloride and 100 mg/100 ml sodium urate. The albumin was dissolved by gentle mixing.
All buffers were boiled before use. Excess sodium urate (approximately 100 mg/100 ml) was added to solutions before titration to prevent pH changes due to the urate itself.
URATE SOLUBILITY IN BIOLOGICAL FLUIDS
All blood and urine samples were obtained from normal volunteers. Blood was drawn in heparinized vacutainers, separated by centrifugation for 10 minutes at 3500 r.p.m. and the plasma frozen at -20°C until the time of assay (not ieases more than 2 weeks). Ultrafiltrates of plasma were prepared by negative pressure ultrafiltration through a collodion membrane. Before assay for urate solubility, three ml aliquots ofsome plasma samples were dialysed for 16 hours at 4°C against 001 mol/l. sodium phosphate buffer, pH 7 4, with or without 0 15 mol/l. sodium chloride. Synovial fluid samples were obtained from patients with inflammatory or traumatic arthritis. None of the subjects from which biological fluid samples were obtained were taking drugs known to inhibit urate binding to macromolecules (Bluestone, Kippen, and Klinenberg, 1969; Whitehouse, Kippen, and Klinenberg, 1971) . 3 ml of each fluid to be tested was placed in a glass test tube with a small magnetic stirring bar. 10 mg sodium urate were added and the sample incubated for 16 hours at 37°C with slow stirring. After 16 hrs each sample was subjected to the centrifugation procedure described above, and the final supernatant assayed for urate.
Results Fig. 1 Fig. 2 shows the effect of pH o bility in 0 01 mol/l. sodiun pH 7 40, containing 0 15 mol/l. sodium chloride. The urate solubility is 6-6 mg/100 ml at 37°C and 3-7 mg/ 100 ml at 26°C. Fig. 3 shows the effect of albumin on sodium urate solubility at 4°C, 26°C, and 37°C. The curves have a sigmoid shape at all temperatures. The increase in urate solubility produced by 50 mg/ml albumin is 45 % at 4°C, 44% at 26°C, and 41 % at 37°C.
.-* Fig. 4 shows the solubility of sodium urate in biological fluids. The mean values in mg/100 ml plus or 0 2 0-3 minus one standard error of the mean are as follows: plasma 10-6 ± 0-5; plasma dialysed against 0 01 on sodium urate solubi-mol/l. sodium phosphate buffer, pH 7*40, 49.5 + 0-6; ?sphate buffer, pH 7 4, plasma dialysed against the same phosphate buffer ? sodium urate (K & K containing 0-15 mol/l. sodium chloride, 10-7 + 0O5S t-squaresfits to the data urine 21-4 ± 1 9; and synovial fluid 10-0 ± 0-7. Dialysing plasma against the sodium chloride-L. sodium chloride, the containing buffer did not change the urate solubility, s than 10 % of the low whereas dialysing plasma against the buffer not conical range from about taining sodium chloride resulted in a fivefold increase tle additional effect of in urate solubility. The mean value for urate solubility )n. Urate solubility is in urine was about twice that of plasma and considerthan at 37°C over the ably more variable. urate from K&K Laboratories. However, the solubility of this urate differed from batch to batch. Certain batches contained amorphous material which assayed as urate but showed a higher solubility (as much as 50% higher) than other K&K batches and the urate prepared in our laboratory. The latter two urate preparations were used in all experiments except those in which the effects ofsodium concentration and of ultrafiltration of plasma were studied.
It is clear that temperature plays a significant role in urate solubility and this has been discussed previously (Wilcox and others, 1972; Allen, Milosovich, and Mattocks, 1965) . Loeb (1972) suggested that the predilection of gout for the peripheral parts of the body is due to sustained lower temperatures in these areas. Most of the experiments in this paper were done at 37°C, but we have included some experiments done at 4°C and 26°C, primarily to allow comparison of our results with the results of other studies done at these temperatures.
That sodium influences urate solubility has been known since at least 1892 when Roberts concluded that salt increases the solubility of uric acid in urine. Bechhold and Ziegler (1914) later showed the opposite to be true. Fig. 1 shows the effect of sodium chloride on urate solubility over a wide concentration range. The physiological range of plasma sodium falls entirely within the flat part of the curve. Thus, changes in plasma sodium would not be great enough to alter urate solubility significantly. Over the electrolyte concentration range in the body one would expect the solubility product to depend somewhat on the nature of other dissolved substances, as well as on the ionic strength itself (Bockris and Reddy, 1970) . Khalaf and Wilcox (1973) found that calcium ion dramatically reduces the solubility of sodium urate in water, while potassium and cupric ion increase the urate solubility slightly. There is also evidence that urea could increase uric acid-urate solubility (Medes, 1932; Sperling, Kedem, and DeVries, 1966) . Seegmiller (1965) , studying the synovial fluid from a patient with acute gout, reported a decrease in pH from 7-4 to 7-2 associated with a rise in lactic acid due to the high rate of glycolysis of leucocytes in the synovial fluid. This observation supported a theory that decreasing pH in the joint during leucocytosis decreases urate solubility slightly. Fig. 2 shows that a decrease in the pH from 7-4 to 7-2 would actually increase the urate solubility slightly. On the other hand, Khalaf and Wilcox (1973) showed that urate nucleation is enhanced by lowering the pH.
The curves shown in Fig. 3 for the effect of albumin on urate solubility are somewhat surprising. Firstly, assuming that the increased solubility is due to binding of urate to albumin, one could predict the early portion of the curves on the basis of saturation of the urate binding sites on the albumin molecules. However, we are presently unable to explain the increased slope at albumin concentrations above 40 mg/mi. Also surprising is that the magnitude of the albumininduced increase in urate solubility is greater, especially at 37°C, than would have been predicted from experiments studying urate binding to albumin by other techniques, such as equilibrium dialysis (Klinenberg and Kippen, 1970; Farrell, Popovich, and Babb, 1971) . Furthermore, our results differ markedly from those of Katz and Schubert (1970) who used a technique similar to the one used in this study to measure the effect of albumin on urate solubility. They reported that an albumin concentration of 120 mg/ml caused an increase in urate solubility of 28 % (from 5-7 to 7-3 mg/100 ml) at 4°C. Our Fig. 3 shows a 100% increase in urate solubility at 4°C and a 60% increase at 37°C at an albumin concentration of 80 mg/ml, and the magnitude of this increase would probably be the same or greater at 120 mg/ml albumin. We cannot explain the discrepancy in results between our laboratories. As seen in Fig. 4 , the high urate solubility of the plasma samples dialysed against a low ionic strength buffer shows the appreciable role of ionic strength in plasma urate solubility. Since the solubility of urate in the plasma samples dialysed against isotonic sodium phosphate buffer was about the same as in the undialysed plasma, this suggests that diffusible ions other than sodium are probably not playing a major role in the plasma solubility of urate. The variability of urate solubilities in the urine samples reflects differences in sodium concentrations and pH. The urate solubility in synovial fluids was slightly less than in plasma. However, these fluids by their nature represent pathological conditions and may not be representative of the fluid in a normal joint space.
The comparison of urate solubility in plasma and plasma ultrafiltrates presented in Fig. 5 further substantiates the conclusion that binding of urate to plasma macromolecules may substantially increase the solubility of urate in plasma. Alvsaker (1968) reported the presence in plasma of a glycoprotein, an al,a2-globulin, which may bind urate in plasma. Katz and Schubert (1970) suggested that a protein polysaccharide (PPL) similar to one found in connective tissue may increase urate solubility in plasma. However, these substances are present in plasma in minute amounts and each molecule would be required to bind large amounts of urate to produce significant increases in urate solubility. Katz and Schubert (1970) reported that PPL at a concentration of 8 mg/ml increases urate solubility by 3-5 times over a control buffer solution. However, this concentration of PPL forms an extremely viscous solution and is many times greater than could occur in plasma. By contrast, the albumin concentrations used in our study (Fig. 3) Of the fluids which we have studied, the plasma ultrafiltrates are perhaps most representative of the in vivo fluids where urate crystallization occurs. If the total urate concentration is the same in the interstitial fluids as in the plasma, this would favour urate crystallization in the interstitial fluids. A similar analysis might apply to the distribution of urate between plasma and synovial fluid, and there is currently some controversy as to whether or not urate levels in the synovial fluid of gouty patients are higher than in the corresponding plasma (Reeves, 1965) .
The solubility studies reported in this paper were done in the presence ofa large excess of urate crystals. However, it is known that if sodium urate crystals are not present then urate can form stable supersaturated solutions. Thus, hyperuricaemic fluids may remain supersaturated with urate until some mechanism causes formation of the first crystals. Urate crystal nucleation may be related to high concentrations of ions, such as calcium, in close proximity to connective tissue, or to interactions between urate and connective tissue components. Studies of these factors are currently proceeding in our laboratories.
Summary
Urate solubility was measured in buffers and body fluids. At physiological concentrations of sodium chloride, urate solubility was less than 10 % of the saltfree value. Minimum urate solubility occurred between pH 7 0 and 10 0 and increased with increasing or decreasing pH. Addition of 50 mg/ml human albumin to buffer caused a 41 % increase in urate solubility at 37°C. The solubility of urate (mg/100 ml) in biological fluids was: plasma 10-6 ± 0.5 (mean + SE); urine 21-4 + 1 9; and synoval fluid 10-0 + 0 7.
Urate may precipitate preferentially in interstitial fluids partly because of the lack of protein molecules to bind it. solubility in vitro. 
Factors affecting urate

